Ask AI
ProCE Banner Activity

Interactive Decision Support Tool: HER2-Positive GEA and BTC Treatment Guidance

Tool

Get recommendations from 5 experts on HER2-positive GEA and BTC for your specific patient case using this interactive decision support tool.

Released: April 24, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with Smart Patients, Inc.

ProCE Banner

Supporters

Supported by an educational grant from Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc.

Partners

Smart Patients, Inc.

ProCE Banner

Target Audience

This activity is designed to address the educational needs of oncologists, advanced practice providers, pharmacists, nurses, and other HCPs involved in caring for patients with GEA or BTC. Additionally, it aims to empower patients with vital information to actively participate in their treatment decisions, fostering a collaborative approach to their care.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate recent practice-changing data from clinical trials of HER2-targeted agents into treatment plans for HER2+ GEA and BTC to improve patient outcomes

  • Develop individualized treatment strategies for HER2+ GEA and BTC based on current and emerging evidence supporting the use of HER2-targeted therapies in this setting

  • Communicate emerging data and ongoing clinical trial opportunities in HER2+ GEA and BTC to educate colleagues and counsel patients, fostering a collaborative environment for decision-making in their treatment journey

  • Identify patients with HER2+ GEA and BTC who could benefit from HER2-targeted therapy

Disclosure

Primary Author

Richard Kim, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, Bayer, Eisai, Elevar, Exelixis, Incyte, Ipsen, Jazz, Roche, Servier, Taiho, Takeda.

Geoffrey Ku, MD: researcher: AstraZeneca, Bristol Myers Squibb, CARsgen, Daiichi Sankyo, I-Mab, Jazz, Merck, Oncolys, Pieris, Triumvira, Zymeworks; consultant/advisor/speaker: Astellas, AstraZeneca, Bayer, BeOne, Bristol Myers Squibb, Daiichi Sankyo, Gilead, I-Mab, Jazz, Merck, Oncolys, Pieris, Zymeworks; other financial or material support: Dava Oncology, I-Mab.

Amit Mahipal, MD, MPH: consultant/advisor/speaker: Astellas, AstraZeneca, Jazz.

Shubham Pant, MD: consultant/advisor: Alligator Bioscience, Arcus, AskGene Pharma, AstraZeneca, Boehringer Ingelheim, BPGBio, Bristol Myers Squibb, Daiichi Sankyo, Immuneering, Ipsen, Janssen, Jazz, Merck, Nihon Medi-Physics, Novartis, Pfizer, Revolution Medicine, Theriva Biosciences, USWorldmeds; researcher (paid to institution): Amal Therapeutics, Arcus, Astellas, Boehringer Ingelheim, Bristol Myers Squibb, CG Pharmaceuticals, Elicio, Immuneering, ImmunoMET, Incyte, Janssen, Jazz, Novartis, Pfizer, Revolution Medicine; individual publicly traded stock/stock options: OncoMed, Telperian.

Rachna T. Schroff, MD, MS, FASCO: consultant/advisor/speaker: AstraZeneca, Boehringer Ingelheim, Boston Scientific, Elevar, Exelixis, Foundation Medicine, Genentech, J-Pharma Co, Merck, Servier, Syneos Health, Zymeworks; researcher: Actuate, Bristol Myers Squibb, Compass, Exelixis, Faeth, Immuno Vaccine, Lisata, Merck, Seagen.